Table 1.
Demographical data and treatment of the nine patients with RA-ILD.
| Patient ID | Age/Sex | RA duration (y) |
ILD duration (y) |
RF/ACPA | Dyspnea | FVC,% (predicted) | DLCO,% (predicted) |
ILD Pattern | ESR | CRP | Steroids/dosage (mg) | Treatment | Other extra-articular | Active arthritis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | 86/F | 2 | 2 | +/+ | yes | 108 | 96 | UIP | 23 | 10 | 5 | nintedanib | no | no |
| 2. | 63/M | 5 | 2 | +/+ | yes | 93 | 40 | UIP-nodules | 88 | 12 | 7,5 | RTX, nintedanib, HCQ | no | no |
| 3. | 69/F | 6 | 3 | +/+ | yes | 58 | 41 | NSIP | 17 | 5 | 5 | RTX, HCQ, nintedanib | no | no |
| 4. | 61/F | 12 | 9 | +/+ | yes | 60 | 33 | UIP | 39 | 6 | 5 | RTX, HCQ, nintedanib | no | no |
| 5. | 72/M | 2 | 2 | +/+ | yes | 98 | 48 | UIP | 20 | 2 | 5 | HCQ, nintedanib | no | no |
| 6. | 60/M | 8 | 2 | +/+ | no | 90 | 64 | UIP | 5 | 4 | 0 | RTX | no | no |
| 7. | 48/M | 14 | 4 | +/+ | no | 98 | 62 | UIP | 12 | 6 | 5 | RTX, MTX | no | no |
| 8. | 72/F | 2 | 2 | -/+ | yes | 79 | 53 | UIP | 6 | 2 | 5 | HCQ, MMF | no | no |
| 9. | 67/F | 4 | 4 | +/- | yes | 94 | 58 | UIP | 20 | 2 | 0 | RTX | no | no |
ACPA, Anti-citrullinated protein antibodies; HCQ, Hydroxychloroquine; MTX, Methotrexate; RA, Rheumatoid arthritis; RF, Rheumatoid factor; RTX, rituximab;UIP, usual interstitial pneumonia.